BridgeBio Pharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BridgeBio Pharma, Inc. - overview
Established
2014
Location
Palo Alto, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2014 by co-founders Neil Kumar Ph. D. (CEO), Seth Merrin, and Frank McCormick Ph. D.
, BridgeBio Pharma, Inc. operates as a clinical-stage biopharmaceutical company that focuses on developing genetically targeted therapies for patients with genetic diseases related to cardiology, neurology, oncology, dermatology, and the endocrine system. In January 2024, BridgeBio Pharma, Inc. raised USD 450 million in venture debt funding from Blue Owl Capital.
The company provides a wide range of genetic disease therapies, such as NULIBRYTM (fosdenopterin), and focuses on advancing potential therapies for genetic conditions and cancers with genetic drivers. Additionally, the firm also provides patient advocacy and clinical trial development services.
Current Investors
KKR, Aisling Capital, Viking Global Investors
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.bridgebio.com/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.